Product Overview
Solaris is one 10 ml vial of an oily blend that carries two sympathomimetic fat-loss agents in a fixed preparation, declared at 5.4 mg per ml in total. Clenbuterol, the first of the two actives, behaves as a beta-2 adrenergic agonist, while yohimbine blocks alpha-2 adrenergic receptors. They operate on the same signalling system from opposite sides, and neither is a steroid.
Because that system, not the hormone axis, is what they touch, nothing here suppresses natural testosterone, nothing aromatizes and there is no recovery block waiting at the end. The reasonable way to read the vial is as a short thermogenic tool that is cycled in blocks and stopped on schedule, with heart rate and blood pressure as the numbers that matter most.
Why the Two Actives Sit Together
A beta-2 agonist raises resting energy expenditure and mobilises stored fat, and an alpha-2 antagonist blocks one of the brakes on that same release. One accelerates the signal and the other removes part of the inhibition, which is why pairing them is common in the cutting products of several brands rather than a feature unique to this vial.
The practical consequence is that the effect is stimulant-shaped. Resting heart rate rises, body temperature climbs slightly, appetite may fall and hands can shake at the top of a dose. Beta-2 receptors also adapt, which is the reason intake is split into two-week blocks with a break between them instead of running continuously at an increasing dose.
Dosage Protocol
There is no approved dose for this blend, and the component concentrations of this particular vial are not disclosed individually. The bands below restate published reference figures for the two actives taken orally and by injection, and they assume separate titration of each one.
| Beginner | Start at 20 mcg of clenbuterol with 5 mg of yohimbine daily, then take two weeks off after two weeks on |
| Intermediate | Clenbuterol 40-80 mcg and yohimbine 10-15 mg a day, in 2-3 blocks of 2 weeks |
| Advanced | Up to 80-120 mcg of clenbuterol daily, with yohimbine capped at 0.2 mg per kg of body weight; the whole course stays inside six to eight weeks |
| Female | The same opening figures, 20-40 mcg plus 5-10 mg daily, inside identical two-week blocks; no confirmed safe protocol is described |
| Administration | Oral or intramuscular; titrate over two to three days and never escalate inside a block |
Monitoring is cardiac and simple: resting pulse and blood pressure measured daily, potassium kept in range because beta-2 agonists lower it, and an electrocardiogram if palpitations persist. Tremor, headache and a racing heart are the signals to reduce or stop rather than wait out.
Suggested Protocols
- Two-week blocks. Run a block, then take two weeks off. The break restores receptor sensitivity, whereas a dose increase inside a block mostly adds side effects.
- Beside a dry anabolic. The Anavar and Winstrol cards cover the non-aromatizing compounds most often stacked with a thermogenic block in a dieting phase.
- A ready-made cutting formula. Where a full injectable cutting stack is preferred, Omnicut 300 supplies the anabolic side in one vial, with this blend handling the metabolic side.
- Never layer stimulants. Caffeine, ephedrine and other beta-agonists are added to the same system; combining them multiplies the cardiac load without adding fat loss.
- Skin as the by-product. Sweating and temperature changes make Accutan a frequent companion in a cutting phase for the resulting skin issues.
What to Expect
- Warm and sweating within days. Raised body temperature and perspiration are typical at the start of a block.
- More energy, less appetite. The stimulant profile resembles ephedrine, and some users eat less without trying.
- Weight moves through expenditure. Any loss comes from a higher calorie burn in a deficit, not from a muscle-building effect, which is not confirmed in people.
- Tremor and palpitations. Frequent and dose dependent, above all when the opening amount is raised too fast.
- Receptor adaptation by week two. The thermogenic response flattens, which is why the block ends rather than the dose rising.
- Cardiac risk is real. Anyone with heart or blood pressure problems should not use a beta-2 agonist at all.
Side Effects and Management
After the Block
No hormonal recovery is required, because this blend does not touch the gonad axis. What does need planning is the exit: the compound is cleared gradually, and clenbuterol remains detectable in urine for up to about fourteen days after the final dose.
Buying This Vial
Solaris is listed in the Xeno Laboratories range beside the single-agent Clenbuterol and the metabolic products T3 and T4. It travels most often with the dry anabolics Anavar and Winstrol, and with Accutan for the skin issues a cutting phase can provoke. Pack size, concentration and availability are shown on each product page.
